The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown. Therefore, tofacitinib effects on synovial pathobiology were investigated. METHODS: A randomised...

詳細記述

保存先:
書誌詳細
出版年:Ann Rheum Dis
主要な著者: Boyle, D L, Soma, K, Hodge, J, Kavanaugh, A, Mandel, D, Mease, P, Shurmur, R, Singhal, A K, Wei, N, Rosengren, S, Kaplan, I, Krishnaswami, S, Luo, Z, Bradley, J, Firestein, G S
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Publishing Group 2015
主題:
Basic and Translational Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4431345/
https://ncbi.nlm.nih.gov/pubmed/25398374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2014-206028
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料